Q-omics provides the consensus-scored IL13RA2 profile across patient tissues and cancer cell-line models. IL13RA2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IL13RA2 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, IL13RA2 protein abundance shows 15,459 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, and GBM as cancer lineages where IL13RA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL13RA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL13RA2 survival associations across molecular data types. IL13RA2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL13RA2 RNA expression–survival associations across cancer types. High IL13RA2 expression shows unfavorable associations in KIRP, ACC and LGG, but favorable associations in LUAD, PAAD and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for IL13RA2 RNA expression.
This table summarizes IL13RA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IL13RA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL13RA2 shows lower tumor expression in KIRP, KICH, LIHC and THCA and higher tumor expression in COAD and HNSC. The KIRP box plot shows higher IL13RA2 RNA expression in normal versus tumor tissue (log2 FC = −2.161, t-test p < 0.001).
This table shows molecular features associated with IL13RA2 in patient tissues and cancer cell lines. In patient samples, IL13RA2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IL13RA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and CNS.
